Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Books

• DiSaia and Creasman Clinical Gynecologic Oncology
  Chase Dana M., Satero Jane, Wenzel Lari B., Monk Bradley J., 19 - Palliative care and quality of life [Book Chapter] 2023
• Clinical Gynecologic Oncology
  Chase Dana M., Wong Siu-Fun, Wenzel Lari B., Monk Bradley J., 20 - Palliative Care and Quality of Life [Book Chapter] 2018
• Clinical Gynecologic Oncology: Eighth Edition
  Chase D. M., Wong S. -F, Wenzel L., Monk Bradley J., Palliative Care and Quality of Life [Book Chapter] 2012

Publications

• Gynecologic oncology
  Bogani Giorgio, Moore Kathleen N., Ray-Coquard Isabelle, Lorusso Domenica, Matulonis Ursula A., Ledermann Jonathan A., González-Martín Antonio, Kurtz Jean-Emmanuel, Raspagliesi Francesco, Pujade-Lauraine Eric, Scambia Giovanni, Caruso Giuseppe, Colombo Nicoletta, Monk Bradley J., Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
  193, p. 30 - 40 2025
• American journal of obstetrics and gynecology
  Levin Gabriel, Monk Bradley J, Pothuri Bhavana, Coleman Robert, Herzog Thomas, Gilbert Lucy, Bernard Laurance, Zeng Xing, Scalia Peter, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies, p. - 2025
• European journal of cancer (1990)
  Oaknin Ana, Monk Bradley J, Lorusso Domenica, Damian Fernanda, Chang Chih-Long, Gotovkin Evgeniy, Pikiel Joanna, Goh Jeffrey C, Hasegawa Kosei, Mora Paulo, Srivastav Ratnesh, Colombo Nicoletta, Fury Matthew G, Tewari Krishnansu S, Polastro Laura, Alia Eva Maria Guerra, Makarova Yulia, Jamil Shaheda, Rischin Danny, Rubio Maria Jesús, Perez Javier, Yoo Suk Young, Gao Bo, Seebach Frank, Lowy Israel, Samouëlian Vanessa, de Melo Andreia Cristina, Kim Hee Seung, Takahashi Shunji, Ramone Daniella, Maćkowiak-Matejczyk Beata, Kim Yong Man, Lisyanskaya Alla S, Mathias Melissa, Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
  216, p. 115146 2025
• Nature reviews. Clinical oncology
  Francoeur Alex A, Monk Bradley J, Tewari Krishnansu S, Treatment advances across the cervical cancer spectrum 2025
• Mirza Mansoor R, Coleman Robert L, Powell Matthew A, Chase Dana M, Slomovitz Brian M, Christensen René de Pont, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Gold Michael A, Hanker Lars C, Stuckey Ashley, Boere Ingrid, Auranen Annika, Raspagliesi Francesco, Pothuri Bhavana, Cibula David, McCourt Carolyn, Shahin Mark S, Gill Sarah E, Monk Bradley J, Stevens Shadi, Copeland Larry J, Tian Min, He Zangdong, Buscema Joseph, Herzog Thomas J, Zografos Eleftherios, A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
• Annals of oncology
  González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
• Cancer research communications
  Zhang Hailei, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Pothuri Bhavana, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Cancer Res Commun
  Zhang Hailei, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A. Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
• Oncology and therapy
  Monk Bradley J., Tekin Cumhur, Keefe Steve, Monberg Matthew, Muston Dominic, van Mens Sophie, Hale Oliver, Boer Jennifer, van Hees Frank, Swami Shilpi, Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024
• Gynecologic oncology
  Hunsberger Kyra, Randall Leslie, Tewari Krishnansu, Monk Bradley, Chase Dana, Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
  190, p. S421 - S421 2024
• Gynecologic oncology
  Konstantinopoulos Panagiotis, Freyer Gilles, Lee Jung-Yun, Gaba Lydia, Marth Christian, Hinson Patsy, Zuradelli Monica, Wang Craig, Su Faye, Miller Michelle, Sehouli Jalid, Cruz Felipe, Cibula David, Monk Bradley, Nyvang Gitte-Bettina, Van Nieuwenhuysen Els, Grisham Rachel, Colombo Nicoletta, Wu Xiaohua, Friedlander Michael, Lorusso Domenica, Glasspool Rosalind, González-Martín Antonio, Kim Jae-Weon, Matulonis Ursula, Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
  190, p. S12 - S12 2024
• Annals of oncology
  Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Toker S, Castonguay V, Arkhipov A, Li K, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
• International journal of gynecological cancer
  Lorusso Domenica, Collins Dearbhaile, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Banerjee Susana, Van Nieuwenhuysen Els, Santin Alessandro, Ring Kari, Colombo Nicoletta, Chon Hye Sook, Clamp Andrew, O’malley David, Monk Bradley, Cortés-Salgado Alfonso, Lustgarten Stephanie, Fabbro Michel, Kalbacher Elsa, Van Gorp Toon, Aghajanian Carol, Youssoufian Hagop, Grisham Rachel, Thaker Premal, Prendergast Emily, Moore Kathleen, LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
  34, p. A13 - A13 2024
• International journal of gynecological cancer
  Oaknin Ana, Lorusso Domenica, Pietzner Klaus, Lee Jung-Yun, Auranen Annika, Cibula David, Lee Yeh Chen, Schilder Russell, Gao Bo, Salutari Vanda, Tan David, Oza Amit, Miller Rowan, Pothuri Bhavana, Tasca Giulia, O’Malley David, Monk Bradley, Wendel Naumann R., Lu Lin, Berman Craig, Borgman Anne, TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
  34, p. A351 - A351 2024
• International journal of gynecological cancer
  Grisham Rachel, Thaker Premal, Oza Amit, Colombo Nicoletta, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, Monk Bradley, Van Nieuwenhuysen Els, Oaknin Ana, Moore Kathleen, Fabbro Michel, O’Malley David, PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
  34, p. A53 - A54 2024
• International journal of gynecological cancer
  Barlin Joyce, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Eshed Helen, Black Destin, Chuang Linus, Cottrill Hope, Hand Lauren, O’Malley David, Chisamore Michael, Durbin Joan, Zheng Pan, Liu Yang, Shpyro Svetlana, Monk Bradley, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Bixel Kristin, Eskander Ramez, Gotlieb Walter, Lee Sun Joo, Lococo Salvatore, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Randall Leslie, Chase Dana, Leitao Mario, Baiocchi Glauco, Black Destin, TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
  34, p. A347 - A347 2024
• European journal of cancer (1990)
  Nakamura Y., Bekaii-Saab T., Hayashi H., Mizuno N., Monk B.J., Nguyen D., Hamilton E., Okines A., O’Malley D.M., Pohlmann P.R., Yu E.Y., Reck M., Pothuri B., Sudo K., Sunakawa Y., Takahashi S., Drees A., Tan S., Stinchcombe T.E., 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
  211, p. 114532 2024
• Annals of oncology
  Monk B.J., González-Martín A., Vergote I., Shahin M.S., Graybill W., Mirza M.R., McCormick C.C., Lorusso D., Heitz F., Moore R.G., Freyer G., O’Cearbhaill R.E., O’Malley D.M., Redondo A., Vulsteke C., Pisano C., Barretina-Ginesta M.P., Pothuri B., Bradley W.H., Haslund C.A., Chase D.M., DiSilvestro P., Gaba L., Holman L.L., Pérez M. J. Rubio, Shtessel L., Herzog T.J., Bruchim I., Compton N., Malinowska I.A., Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Future oncology (London, England)
  Mirza Mansoor R, Chase Dana M, Black Destin, Gilbert Lucy, Pothuri Bhavana, Cibula David, Monk Bradley J, Buscema Joseph, Coleman Robert L, Valabrega Giorgio, Landrum Lisa M, Hanker Lars C, Slomovitz Brian M, Christensen René dePont, Novák Zoltán, Sharma Sudarshan, Stuckey Ashley, Boere Ingrid, Gold Michael A, Auranen Annika, Gill Sarah E, McCourt Carolyn, Raspagliesi Francesco, Shahin Mark S, Herzog Thomas J, Copeland Larry J, Tian Min, He Zangdong, Stevens Shadi, Zografos Eleftherios, Powell Matthew A, A Plain Language Summary of 'Dostarlimab for primary advanced or recurrent endometrial cancer', p. 1 2024
• Journal of clinical oncology
  Lee Yeh Chen, Castellano Tara, Myers Tashanna K. N., Barnes Elizabeth H, Chase Dana Meredith, McCormick Colleen, Diamante Katrina, Shannon Catherine M., Small William, Huh Warner King, Lea Jayanthi Sivasothy, Walker Joan L., Miller Katherine, Moore Kathleen N., Govindarajulu Geetha, Monk Bradley J., Stockler Martin R, Mileshkin Linda R., Bae-Jump Victoria Lin, Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
  42:16_suppl, p. 1594 - 1594 2024
• Gynecologic oncology
  Pothuri Bhavana, Burger Robert A., Gaba Lydia, Van Le Linda, Guerra Eva, Bender David, Baurain Jean-François, Korach Jacob, Cloven Noelle, Churruca Cristina, Follana Philippe, DiSilvestro Paul, Bacqué Emeline, Jardon Kris, Pisano Carmela, Peen Ulla, Mäenpää Johanna, Gupta Divya, Li Yong, Compton Natalie, Antonova Jenya, Monk Bradley J., González-Martín Antonio, Heitz Florian, Han Sileny, Chase Dana M., Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
  184, p. 168 - 177 2024
• Gynecologic oncology reports
  Rimel Bobbie J., Chase Dana M., Perhanidis Jessica, Ghazarian Armen A., Du Ella Xiaoyan, Wang Travis, Song Jinlin, Golembesky Amanda K., Hurteau Jean A., Kalilani Linda, Salani Ritu, Monk Bradley J., Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set, p. 101332 2024
• Perhanidis Jessica, Ghazarian Armen, Du Ella, Wang Travis, Song Jinlin, Golembesky Amanda, Hurteau Jean, Rimel Bobbie, Kalilani Linda, Salani Ritu, Monk Bradley, Chase Dana, Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set 2024
• Gynecologic oncology
  Mirza Mansoor, Slomovitz Brian, Christensen René DePont, Novak Zoltan, Chase Dana, Landrum Lisa, He Zangdong, Black Destin, Gilbert Lucy, Sharma Sudarshan, Valabrega Giorgio, Hanker Lars, Stuckey Ashley, Boere Ingrid, Gold Michael, Gill Sarah, Monk Bradley, Stevens Shadi, Coleman Robert, Powell Matthew, Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)
  176, p. S43 - S44 2023
• Journal of minimally invasive gynecology
  Stewart Chelsea, Moreno Andrea, Vo Elise, Bhattarai Bikash, Farley John, Willmott Lyndsay, Monk Bradley, Chase Dana, Factors associated with inpatient narcotic medication usage after robotic assisted laparoscopy 2023
• Journal of geriatric oncology
  Moore Madison S., Willmott Lyndsay J., Chase Dana M., Vo Elise H., Bhattarai Bikash, Farley John H., Monk Bradley J., Robotic-assisted gynecologic surgery in an older population: A comparison study
  14:6, p. 101533 - 101533 2023
• The New England journal of medicine
  Mirza Mansoor R, Chase Dana M, Slomovitz Brian M, dePont Christensen René, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Pothuri Bhavana, Boere Ingrid, Gold Michael A, Auranen Annika, Cibula David, McCourt Carolyn, Raspagliesi Francesco, Buscema Joseph, Shahin Mark S, Gill Sarah E, Monk Bradley J, Herzog Thomas J, Copeland Larry J, Tian Min, Coleman Robert L, He Zangdong, Stevens Shadi, Zografos Eleftherios, Powell Matthew A, , Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, p. - 2023
• Journal of clinical oncology
  Bixel Kristin Leigh, Leitao Mario M., Chase Dana Meredith, Quick Allison, Lim Peter C, Eskander Ramez Nassef, Gotlieb Walter H., LoCoco Salvatore, Walker Joan L., Martino Martin A, McCormick Colleen, Myers Tashanna K. N., Tewari Krishnansu Sujata, Slomovitz Brian M., Randall Leslie M., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer
  40:16_suppl, p. TPS5605 - TPS5605 2022
• International journal of gynecological cancer
  Chase D M, Backes F, Han S, Graybill W, Romeo Marin M, Lund B, Pothuri B, Mangili G, O’malley D, Berton D, Willmott L, Baumann K, Coleman R, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl F, Woodward T, Monk B J, Gonzalez-Martin A, 961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial
  31:Suppl 3, p. A284 - A284 2021
• Gynecologic oncology
  Chase Dana M, Neighbors Jordan, Perhanidis Jessica, Monk Bradley J, Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay
  161:3, p. 832 - 837 2021
• International journal of gynecological cancer
  Mäenpää Johanna, Pothuri Bhavana, Han Sileny, Chase Dana, Bender David, Follana Philippe, Bacque Emeline, Yong L I, González-Martin Antonio, Monk Bradley J, 294 Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial
  30:Suppl 4, p. A63 - A64 2020
• International journal of gynecological cancer
  Freyer G, Pothuri B, Han S, Chase D, Monk B, Heitz F, Burger R, Gaba L, Van Le L, Guerra E, Peen U, Bender D, Korach J, Baurain J F, Jardon K, Pisano C, Maenpaa J, González-Martín A, Bacque E, Li Y, Eliason L, DiSilvestro P, Cloven N, Churruca C, Follana P, Hoskins P, 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
  30:Suppl 3, p. A12 - A13 2020
• Gynecologic oncology
  Eakin Cortney M., Norton Taylor J., Monk Bradley J., Chase Dana M., Management of nausea and vomiting frompoly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer
  159:2, p. 581 - 587 2020
• Heitz F, Monk B J, Gaba L, Korach J, Van Le L, Guerra E, Bender D, Cloven N, Follana P, Maenpaa J, Baurain J F, Pisano C, Peen U, Bacque E, Li Y, Burger R, González-Martin A, Pothuri B, Han S, Chase D, Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 2020
• Gynecologic oncology
  Eakin C., Ewongwo A., Pendleton L., Chase D.M., Monk B.J., Real-world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice: The clinical and financial burden
  159, p. 139 - 139 2020
• Gynecologic oncology
  Eakin Cortney M., Ewongwo Agnes, Pendleton Lee, Monk Bradley J., Chase Dana M., Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice
  159:1, p. 112 - 117 2020
• Annals of oncology
  Pothuri B., Han S., Chase D., Heitz F., Burger R., Gaba L., Van Le L., Cloven N.G., Guerra E., Bender D., Korach J., Follana P., Maenpaa J., Baurain J-F., Pisano C., Peen U., Bacqué E., Li Y., Martín A. González, Monk B.J., 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
  31, p. S612 - S613 2020
• International journal of gynecological cancer
  Chase Dana, Leitao Mario, Oaknin Ana, Huh Warner K, Pulaski Heather L, Robison Katina, Guntupalli Saketh R, Richardson Debra, Salani Ritu, Sill Michael W, Wenzel Lari B, Gil Karen, Tewari Krishnansu Sujata, Huang Helen Q, Monk Bradley J, Ramondetta Lois Michelle, Penson Richard T, Landrum Lisa M, Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
  30:5, p. 596 - 601 2020
• Gynecologic oncology
  Eakin C., Ewongwo A., Chase D., Monk B., A Qualitative Evaluation of Clinical Burden of Poly (ADP-ribose) Polymerase Inhibitor Usage in a Community Oncology Practice
  156:3, p. e23 - e24 2020
• Scientific reports
  Łaniewski Paweł, Cui Haiyan, Roe Denise J., Barnes Dominique, Goulder Alison, Monk Bradley J., Greenspan David L., Chase Dana M., Herbst-Kralovetz Melissa M., Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis
  9:1, p. 7333 - 7333 2019
• Gynecologic oncology
  Liang J., Monk B.J., Wolsiefer K., Stone J., Chase D.M., Evidence of provider implicit bias toward women with cervical cancer: A study of physicians and nurses caring for gynecologic oncology patients
  149, p. 137 - 137 2018
• Journal of Oncology Medicine & Practice
  Barnes Dominique, Rivera O Richard, Monk J Bradley, Chase Dana, Clinic-based Depression Screening in Gynaecologic Oncology Patients Using the Patient Health Questionnaires-2 (PHQ-2): Are we Identifying the Highest Risk Patients at their Initial Visit?
  3:2 2018
• Gynecologic oncology
  Moreno A., Vo Elise, Bhattarai B., Patel S., Farley J., Willmott L., Monk B., Chase D., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, Monk Bradley J., Chase Dana, Shields Kristin M., Willmott Lyndsay J., Farley John, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Barnes Dominique, Willmott Lyndsay J., Farley John, Monk Bradley J., Chase Dana, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Vo E.H., Moreno A.E., Bhattarai B., Patel S., Farley J.H., Monk B.J., Willmott L.J., Chase D.M., Robotic-assisted Gynecologic Surgery in an Elderly Population: A Comparison Study
  147:1, p. 204 - 205 2017
• Gynecologic Oncology
  Graybill W. S., Pothuri B., Chase Dana M., Monk Bradley J., Poly(ADP-Ribose) Polymerase (PARP) Inhibitors as Treatment Versus Maintenance in Ovarian Carcinoma
  146:1, p. 11 - 15 2017
• Gynecologic Oncology
  Chase Dana M., Monk Bradley J., Chaplin D. J., The Development and use of Vascular Targeted Therapy in Ovarian Cancer
  145:2, p. 393 - 406 2017
• Gynecologic oncology
  Haverland Rachael, Chase Dana, Gardner Austin B., Monk Bradley, Chan John K., Does Lymphadenectomy Affect Treatment Allocation in the Elderly Endometrial Cancer Population?
  143:1, p. 217 - 217 2016
• Gynecologic oncology research and practice
  Minion Lindsey E., Chase Dana M., Farley John H., Willmott Lyndsay J., Monk Bradley J., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Obstetrics and gynecology (New York. 1953)
  Chase Dana M, Craig Christine D, Fedewa Stacey A, Virgo Katherine S, Farley John H, Halpern Michael, Monk Bradley J, Lin Chun Chieh, Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors
  126:4, p. 792 - 802 2015
• Gynecologic Oncology
  Chase Dana M., Goulder A., Zenhausern F., Monk Bradley J., Herbst-Kralovetz M., The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment
  138:1, p. 190 - 200 2015
• Gynecologic oncology
  Shields K., Craig C., Baxter L., Renda L., Pipe J., Monk B., Chase D., Abstract 15: Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy
  137:3, p. 596 - 596 2015
• Gynecologic oncology
  Shields K.M., Willmott L., Farley J.H., Monk B.J., Chase D., Factors associated with low educational background in uterine cancer patients
  137, p. 123 - 123 2015
• Gynecologic oncology
  Minion Lindsey E., Dolinsky Jill S., Dunlop Charles L., Chao Elizabeth C., Chase Dana M., Monk Bradley J., Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
  137:1, p. 86 - 92 2015
• Gynecologic oncology
  Chase Dana M., Huang Helen, Foss Cassandra D., Wenzel Lari B., Monk Bradley J., Burger Robert A., Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study
  136:2, p. 323 - 327 2015
• International Journal of Gynecological Cancer
  Chase Dana M., Long Harry J.,,III, Monk Bradley J., Wenzel Lari, Ramondetta Lois, Cella David, Kauderer James, Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer An Exploratory Analysis of NRG Oncology/Gynecologic Oncology Group Trials 179 and 204
  25:2, p. 303 - 308 2015
• Gynecologic Oncology
  Osann K., Hsieh S., Monk Bradley J., Chase D., Cella D., Wenzel L., Nelson E. L., Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials
  135:2, p. 266 - 272 2014
• Gynecologic oncology research and practice
  Foss Cassandra D, Farley John H, Dalton Heather J, Monk Bradley J, Chase Dana M, Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
  1:1, p. 4 - 4 2014
• Gynecologic oncology research and practice
  Gibson Steven J, Tewari Krishnansu S, Monk Bradley J, Chase Dana M, Updates on drug discovery in ovarian cancer
  1:1, p. 3 - 3 2014
• International Journal of Gynecological Cancer
  Liang Winnie S., Nasser Sara, Aldrich Jessica, Kurdoglu Ahmet, McDonald Jacquelyn, Izatt Tyler, Christoforides Alexis, Baker Angela, Craig Christine, Egan Jan B., Chase Dana M., . . . Monk, Bradley J., Monk Bradley J., Phillips Lori, Reiman Rebecca, Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing
  24:2, p. 329 - 338 2014
• Supportive care in cancer
  Craig Christine D, Chase Dana M, Monk Bradley J, Farley John H, Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment
  22:1, p. 279 - 287 2014
• Gynecologic oncology
  Craig C., Gibson S.J., Osann K.E., Farley J., Willmott L., Monk B.J., Chase D.M., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Gynecologic oncology
  Craig C., Gibson S., Osann K., Farley J., Monk B., Chase D., Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
  130:1, p. e31 - e32 2013
• Gynecologic oncology
  Craig C., Lin C., Fedewa S., Virgo K., Farley J., Monk B., Chase D., Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
  130:1, p. e163 - e163 2013
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., Dalton Heather, Farley John H., Chase Dana M., Benjamin Ivor, Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• European Journal of Gynaecological Oncology
  Jordan S. M., Chase D. M., Watanabe T., Osann K., Monk Bradley J., Rutgers J. K., High pathologic misdiagnosis of cervical adenocarcinoma in situ
  34:5, p. 446 - 449 2013
• Gynecologic Oncology
  Chase Dana M., Sill Michael W., Monk Bradley J., Chambers Mark D., Darcy Kathleen M., Han Ernest S., Buening Barbara J., Sorosky Joel I., Fruehauf John P., Burger Robert A., Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory a
  126:3, p. 375 - 380 2012
• Expert review of pharmacoeconomics & outcomes research
  Chase Dana M., Wenzel L. B., Monk Bradley J., Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer
  12:3, p. 279 - 281 2012
• Gynecologic Oncology
  Chase Dana M., Huang Helen Q., Wenzel Lari, Cella David, McQuellon Richard, Long Harry J., Moore David H., Monk Bradley J., Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study
  125:2, p. 315 - 319 2012
• Gynecologic Oncology
  Chase Dana M., Kauderer J., Wenzel L., Long H., Cella D., Monk Bradley J., Factors associated with grade 3–4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of Gynecologic Oncology Group trials (GOG) 179 and 204
  125, Supplement 1:0, p. S115 - S116 2012
• Gynecologic oncology
  Osann Kathryn, Wenzel Lari, Dogan Aysun, Hsieh Susie, Chase Dana M., Sappington Sandra, Monk Bradley J., Nelson Edward L., Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial
  121:3, p. 558 - 564 2011
• Gynecologic oncology
  Chase D., Sill M., Chambers M., Darcy K., Han E., Fruehauf J., Monk B., Buening B., Sorosky J., Burger R., Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial
  120, p. S65 - S66 2011
• Gynecologic oncology
  Han Ernest S., DeGeest Koen, Fruehauf John P., Burger Robert A., Darcy Kathleen M., Sill Michael W., Randall Leslie M., Greer Benjamin E., Chase Dana, Parmakhtiar Basmina, Monk Bradley J., Connelly Patrick, Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
  119:3, p. 484 - 490 2010
• Future oncology (London, England)
  Chase Dana M., Watanabe Tawny, Monk Bradley J., Assessment and significance of quality of life in women with gynecologic cancer
  6:8, p. 1279 - 1287 2010
• American journal of obstetrics and gynecology
  Chase Dana M., Monk Bradley J., Pugmire Gordon A., Lopez Sarah, Nguyen Christina, A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?
  199:5, p. 541.e1 - 541.e7 2008
• Expert review of anticancer therapy
  Chase Dana M., Monk Bradley J., Wenzel Lari B., Tewari Krishnansu S., Supportive care for women with gynecologic cancers
  8:2, p. 227 - 241 2008